Vitamin D binding protein macrophage-activating factor - Efranat
Alternative Names: EF-022; GcMAF; Globulin component macrophage activating factorLatest Information Update: 28 Sep 2020
At a glance
- Originator Einstein Medical Center
- Developer Efranat; Socrates Institute for Therapeutic Immunology
- Class Antineoplastics; Carrier proteins; Lymphokines
- Mechanism of Action Macrophage activating factor replacements; Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Recurrent respiratory papillomatosis; Solid tumours
- Discontinued Breast cancer; Colorectal cancer; Prostate cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Recurrent-respiratory-papillomatosis in Israel (Parenteral)
- 28 Dec 2019 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Recurrent) in Israel (IM, Injection)
- 11 Dec 2017 Phase I development for Solid tumours is ongoing in Israel (Efranat pipeline, December 2017)